Display options
Cite
Krenz B, Gebhardt-Wolf A, Ade CP, et al. MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2021;81(16):4242-4256doi: 10.1158/0008-5472.CAN-21-1677.
Krenz, B., Gebhardt-Wolf, A., Ade, C. P., Gaballa, A., Roehrig, F., Vendelova, E., Baluapuri, A., Eilers, U., Gallant, P., D'Artista, L., Wiegering, A., Gasteiger, G., Rosenfeldt, M. T., Bauer, S., Zender, L., Wolf, E., & Eilers, M. (2021). MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer research, 81(16), 4242-4256. https://doi.org/10.1158/0008-5472.CAN-21-1677
Krenz, Bastian, et al. "MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma." Cancer research vol. 81,16 (2021): 4242-4256. doi: https://doi.org/10.1158/0008-5472.CAN-21-1677
Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, Baluapuri A, Eilers U, Gallant P, D'Artista L, Wiegering A, Gasteiger G, Rosenfeldt MT, Bauer S, Zender L, Wolf E, Eilers M. MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2021 Aug 15;81(16):4242-4256. doi: 10.1158/0008-5472.CAN-21-1677. Epub 2021 Jun 18. PMID: 34145038; PMCID: PMC7611539.
Copy Download .nbib Format: NLM
Share it on

Cancer Res. 2021 Aug 15;81(16):4242-4256. doi: 10.1158/0008-5472.CAN-21-1677. Epub 2021 Jun 18.

MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma.

Cancer research

Bastian Krenz, Anneli Gebhardt-Wolf, Carsten P Ade, Abdallah Gaballa, Florian Roehrig, Emilia Vendelova, Apoorva Baluapuri, Ursula Eilers, Peter Gallant, Luana D'Artista, Armin Wiegering, Georg Gasteiger, Mathias T Rosenfeldt, Stefan Bauer, Lars Zender, Elmar Wolf, Martin Eilers

Affiliations

  1. Department of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, University of Würzburg, Würzburg, Germany.
  2. Comprehensive Cancer Center Mainfranken, Core Unit Bioinformatics, Biocenter, University of Würzburg, Würzburg, Germany.
  3. Institute of Systems Immunology, University of Würzburg, Würzburg, Germany.
  4. Department of Biochemistry and Molecular Biology, Cancer Systems Biology Group, Biocenter, University of Würzburg, Würzburg, Germany.
  5. Core Unit High-Content Microscopy, Biocenter, University of Würzburg, Würzburg, Germany.
  6. Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, Tübingen, Germany.
  7. Department of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital Würzburg, Würzburg, Germany.
  8. Institute for Pathology, University of Würzburg, Würzburg, Germany.
  9. Institute for Immunology, BMFZ, Philipps-University of Marburg, Marburg, Germany.
  10. Department of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, University of Würzburg, Würzburg, Germany. [email protected].

PMID: 34145038 PMCID: PMC7611539 DOI: 10.1158/0008-5472.CAN-21-1677

Abstract

Deregulated expression of the MYC oncoprotein enables tumor cells to evade immune surveillance, but the mechanisms underlying this surveillance are poorly understood. We show here that endogenous MYC protects pancreatic ductal adenocarcinoma (PDAC) driven by KRAS

©2021 American Association for Cancer Research.

References

  1. Nat Rev Mol Cell Biol. 2020 May;21(5):255-267 - PubMed
  2. EMBO J. 1988 Apr;7(4):1023-9 - PubMed
  3. Nature. 2014 Dec 18;516(7531):436-9 - PubMed
  4. Annu Rev Immunol. 2018 Apr 26;36:667-694 - PubMed
  5. NPJ Genom Med. 2020 Dec 11;5(1):55 - PubMed
  6. Cell. 2017 Nov 30;171(6):1284-1300.e21 - PubMed
  7. Cell. 2012 Mar 30;149(1):22-35 - PubMed
  8. Cancer Discov. 2020 Jun;10(6):872-887 - PubMed
  9. Annu Rev Immunol. 2015;33:257-90 - PubMed
  10. Mol Cell. 2018 Sep 20;71(6):1051-1063.e6 - PubMed
  11. Nature. 2015 Apr 23;520(7548):553-7 - PubMed
  12. Clin Exp Immunol. 2008 Nov;154(2):270-84 - PubMed
  13. Cancer Cell. 2005 May;7(5):469-83 - PubMed
  14. Nat Commun. 2015 Apr 09;6:6744 - PubMed
  15. Mol Cell Biol. 2005 Jul;25(14):6225-34 - PubMed
  16. Cold Spring Harb Perspect Med. 2013 Dec 01;3(12):a014290 - PubMed
  17. Cancer Discov. 2020 Apr;10(4):588-607 - PubMed
  18. Nature. 2017 Aug 24;548(7668):461-465 - PubMed
  19. Nat Commun. 2013;4:2535 - PubMed
  20. Cancer Discov. 2020 Jan;10(1):26-39 - PubMed
  21. Science. 2016 Apr 8;352(6282):227-31 - PubMed
  22. Curr Genet. 2019 Aug;65(4):905-912 - PubMed
  23. Immunity. 2006 Feb;24(2):153-63 - PubMed
  24. Nature. 2019 Jan;565(7737):43-48 - PubMed
  25. Hum Mol Genet. 2015 Aug 1;24(15):4429-42 - PubMed
  26. Nature. 2015 Sep 17;525(7569):384-8 - PubMed
  27. Nat Rev Mol Cell Biol. 2016 Feb;17(2):83-96 - PubMed
  28. Nature. 2014 Jul 24;511(7510):483-7 - PubMed
  29. Mol Cell. 2020 Mar 19;77(6):1322-1339.e11 - PubMed
  30. J Am Chem Soc. 2011 Mar 23;133(11):3764-7 - PubMed
  31. Nat Rev Immunol. 2018 May;18(5):309-324 - PubMed
  32. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):258-63 - PubMed
  33. Front Immunol. 2019 Jul 17;10:1586 - PubMed
  34. Cancer Cell. 2021 Apr 12;39(4):494-508.e5 - PubMed
  35. Nature. 2018 Aug;560(7717):238-242 - PubMed
  36. Cancer Cell. 2018 Nov 12;34(5):807-822.e7 - PubMed
  37. Autophagy. 2018;14(8):1435-1455 - PubMed
  38. Cell. 2021 Jan 21;184(2):384-403.e21 - PubMed
  39. Cell. 2017 Nov 30;171(6):1301-1315.e14 - PubMed
  40. Nat Commun. 2020 Jun 5;11(1):2860 - PubMed
  41. Nat Immunol. 2003 May;4(5):491-6 - PubMed
  42. Front Immunol. 2021 Mar 09;12:636568 - PubMed

Publication Types

Grant support